期刊文献+

趋化因子及其受体与乳腺癌骨转移

下载PDF
导出
摘要 随着综合治疗的发展,乳腺癌患者的生存率得到明显的提高,但生活质量并未得到改善。乳腺癌骨转移的发生率很高,骨转移后引起骨质疏松、高钙血症、脊髓压迫和病理性骨折等骨相关事件严重影响到乳腺癌患者的生存和生活质量。肿瘤的转移是非随机的、多步骤的复杂过程,其间涉及到肿瘤细胞和转移部位微环境间的相互作用。本文就趋化因子及其受体与乳腺癌骨转移的关系进行阐述。
出处 《癌症进展》 2010年第2期160-163,共4页 Oncology Progress
  • 相关文献

参考文献30

  • 1Balkwill F. Chemokine biology in cancer [J]. Semin Immunol, 2003, 15:49.
  • 2Ji MW, Xi YD, Wang HG, et al. Chemokines and their role in tumor growth and metastasis [J]. Immunol Methods, 1998, 220 : 1.
  • 3郑红.趋化因子及其受体的功能[J].免疫学杂志,2004,20(1):1-5. 被引量:52
  • 4张建平,谢幸,吕卫国.趋化因子与肿瘤的定向转移[J].国外医学(肿瘤学分册),2005,32(5):351-354. 被引量:8
  • 5ZlotniK A, Yoshie O. Chemokines: A new classification system and their role in immunity [J]. Immunity, 2000, 12 : 121.
  • 6Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer [ J ]. Clin Cancer Res, 2000, 6 (8) : 3282.
  • 7Matt JC, Robert DL. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases [ J]. Cancer Metastasis Rev, 2006, 25 : 611.
  • 8Bendre MS, Kurten DG, Foote TM, et al. Suva expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo [J]. Cancer Research, 2002, 62:5571.
  • 9Bendre MS, Montague DC, Peery T, et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease [J]. Bone, 2003, 33 (1):28.
  • 10Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer [ J ]. Clin Cancer Res Treat, 2001, 7:285.

二级参考文献66

  • 1马飞,宁力,张颖妹,徐兵河.趋化因子受体CCR7促进乳腺癌细胞的趋化与侵袭[J].第四军医大学学报,2004,25(20):1883-1886. 被引量:21
  • 2王新友,王岭,王辉,李南林,王廷.乳腺癌患者血浆基质金属蛋白酶-2,-9的明胶酶谱分析[J].第四军医大学学报,2005,26(11):1015-1017. 被引量:2
  • 3李伟,张建国.乳腺癌中肿瘤相关淋巴管生成[J].中国现代普通外科进展,2005,8(2):67-68. 被引量:2
  • 4[1]Yoshie O, Imai T, Nomiyama H. Chemokines in immunity[J]. Adv Immunol, 2001,78:57-110.
  • 5[2]Cascieri MA, Springer MS. The chemokine/chemokine-receptor family: potential and progress for therapeutic interven-tion[J]. Curr Opin Chem Bio,2000,4(4):420-427.
  • 6[3]Christopherson K 2nd, Hromas R. Chemokine regulation of normal and pathologic immune responses[J]. Stem Cells,2001,19(5):388-396.
  • 7[4]Murphy PM, Baggiolini M, Charo IF. International union of pharmacology. XXII. Nomenclature for chemokine receptors[J]. Pharmacol Rev,2000,52(1): 145-176.
  • 8[5]Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines[J]. Annu Rev Pharmacol Toxicol,2002,42:469-499.
  • 9[6]Luo J, Luo Z, Zhou N, et al. Attachment of C-terminus of SDF-1 enhances the biological activity of its N-terminal peptide[J]. Bioch Biophy Res Communicat,1999,264(1):42-47.
  • 10[7]Amara A, Lorthioir O, Valenzuela A, et al. SDF-1( associates with heparin sulfates through the first β-strand of the chemokine[J]. J Bio Chem,1999,274(34):23 916-23 925.

共引文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部